Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GLEN ALLEN, VA., JUNE 16, 2026 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY) TODAY ANNOUNCED THAT THE COMPANY'S COMPENSATION COMMITTEE AND BOARD OF DIRECTORS GRANTED MATTHEW DAVIDSON AND JULIE SAIKI, THE COMPANY'S NEWLY APPOINTED CHIEF DEVELOPMENT OFFICER AND EXECUTIVE VICE PRESIDENT OF STRATEGY, RESPECTIVELY, RESTRICTED STOCK UNITS AND STOCK OPTIONS TO PURCHASE COMPANY COMMON STOCK AS AN INDUCEMENT TO THEM BECOMING EMPLOYEES OF THE COMPANY IN CONNECTION WITH THE CLOSING OF ITS BUSINESS COMBINATION WITH AZORA THERAPEUTICS, INC. (AZORA), WHICH WAS PREVIOUSLY ANNOUNCED BY THE COMPANY ON JUNE 11, 2026.

ADIAL PHARMACEUTICALS EXPANDS EXECUTIVE LEADERSHIP TEAM AND CLOSES PIPE FINANCING

- ACQUISITION OF AZORA AND CONCURRENT PRIVATE PLACEMENT POSITIONS THE COMBINED COMPANY TO ADVANCE ITS PIPELINE THROUGH KEY CLINICAL MILESTONES IN ULCERATIVE COLITIS, INCLUDING PHASE 1 INITIATION IN MID-2027

ADIAL PHARMACEUTICALS ANNOUNCES ACQUISITION OF AZORA THERAPEUTICS AND UP TO $64 MILLION FINANCING

GLEN ALLEN, VA., MAY 11, 2026 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL)(ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE 2026 FIRST QUARTER ENDED MARCH 31, 2026.

ADIAL PHARMACEUTICALS REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW U.S. UTILITY PATENT APPLICATION TARGETING PATIENT POPULATIONS WITH DEMONSTRATED HEIGHTENED RESPONSIVENESS TO ONDANSETRON TREATMENT, REINFORCING ADIAL'S PRECISION-MEDICINE APPROACH NEW U.S. UTILITY PATENT APPLICATION TARGETING PATIENT POPULATIONS WITH DEMONSTRATED HEIGHTENED RESPONSIVENESS TO ONDANSETRON TREATMENT, REINFORCING ADIAL'S PRECISION-MEDICINE APPROACH

ADIAL PHARMACEUTICALS ADVANCES IP PORTFOLIO WITH NEW U.S. UTILITY PATENT APPLICATION, POSITIONING FOR POTENTIAL MARKET EXCLUSIVITY THROUGH 2045

VOUCHER APPLICATION DETAILS FOCUS ON AUD AS A MAJOR DRIVER OF THE U.S. SUBSTANCE USE CRISIS AND THE GENETIC TARGETING OF AD04'S ROLE IN PROVIDING A TREATMENT OPTION FOR PATIENTS WHERE EXISTING TREATMENTS INADEQUATELY ADDRESS PATIENT OUTCOMES VOUCHER APPLICATION DETAILS FOCUS ON AUD AS A MAJOR DRIVER OF THE U.S. SUBSTANCE USE CRISIS AND THE GENETIC TARGETING OF AD04'S ROLE IN PROVIDING A TREATMENT OPTION FOR PATIENTS WHERE EXISTING TREATMENTS INADEQUATELY ADDRESS PATIENT OUTCOMES

ADIAL PHARMACEUTICALS SUBMITS APPLICATION TO FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM FOR AD04 CLINICAL DEVELOPMENT PROGRAM

DEMONSTRATION BATCH PRODUCTION ACHIEVES ALL PRESPECIFIED TEST SPECIFICATIONS FOR DISSOLUTION, CONTENT UNIFORMITY, BLEND UNIFORMITY MEETING REGULATORY REQUIREMENTS TO START CLINICAL DRUG PRODUCT PRODUCTION DEMONSTRATION BATCH PRODUCTION ACHIEVES ALL PRESPECIFIED TEST SPECIFICATIONS FOR DISSOLUTION, CONTENT UNIFORMITY, BLEND UNIFORMITY MEETING REGULATORY REQUIREMENTS TO START CLINICAL DRUG PRODUCT PRODUCTION

ADIAL PHARMACEUTICALS SUCCESSFULLY COMPLETES MANUFACTURING OF DEMONSTRATION BATCH PRODUCTION, ENABLING CLINICAL AND REGISTRATION PRODUCTION FOR AD04 PLANNED PHASE 3 TRIAL

COMPANY HIGHLIGHTS ADVANCED PARTNERING DISCUSSIONS AS AD04 ADVANCES TOWARD PHASE 3 COMPANY HIGHLIGHTS ADVANCED PARTNERING DISCUSSIONS AS AD04 ADVANCES TOWARD PHASE 3

ADIAL PHARMACEUTICALS REGAINS FULL COMPLIANCE WITH NASDAQ LISTING REQUIREMENT

REGULATORY SHIFT COULD SIGNIFICANTLY LOWER PHASE 3 COSTS AND ACCELERATE PATH TOWARD NDA SUBMISSION FOR AD04 REGULATORY SHIFT COULD SIGNIFICANTLY LOWER PHASE 3 COSTS AND ACCELERATE PATH TOWARD NDA SUBMISSION FOR AD04

ADIAL PHARMACEUTICALS HIGHLIGHTS FDA POLICY DIRECTION THAT MAY REDUCE PIVOTAL TRIAL BURDEN FROM TWO STUDIES TO ONE

GLEN ALLEN, VA., FEB. 04, 2026 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY APPLAUDED THE PASSAGE BY CONGRESS AND SIGNING INTO LAW BY PRESIDENT DONALD J. TRUMP OF THE DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES APPROPRIATIONS BILL, 2026.

ADIAL APPLAUDS CONGRESSIONAL DIRECTIVE ADVANCING ALTERNATIVE CLINICAL TRIAL ENDPOINTS FOR SUBSTANCE USE DISORDERS, STRENGTHENING REGULATORY PATH FOR AD04

COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON FEBRUARY 6, 2026 COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON FEBRUARY 6, 2026

Adial Pharmaceuticals, Inc.

ADIL

Price

Financial Reports

No items found.

Press Releases

Adial Pharmaceuticals, Inc.

ADIL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ADIL